|
rs61764370
|
|
Neoplasm Metastasis
|
|
0.020 |
GeneticVariation
|
BEFREE |
Results demonstrated that TT genotype and T allele of rs712 were associated with the increased risk of CRC; the patients with GG genotype and G allele of rs61764370 had a shorter survival and a higher risk of relapse or metastasis of CRC.
|
26515332 |
2016 |
|
rs61764370
|
|
Neoplasm Metastasis
|
|
0.020 |
GeneticVariation
|
BEFREE |
The objective of the present study was to explore the molecular mechanism with which a single nucleotide polymorphism (rs61764370) interferes with the interaction between the 3'-untranslated region (3'-UTR) of Kirsten rat sarcoma viral oncogene homolog (KRAS) and let-7a, and its association with the metastasis of osteosarcoma (OS).
|
27430246 |
2016 |
|
rs61764370
|
|
Non-Small Cell Lung Carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
We have reported the analysis performed on the role of the polymorphism located in the KRAS-LCS (rs61764370) which is involved in the disruption of the let-7 complementary site in NSCLC patients enrolled within the TAILOR trial, a randomised trial comparing erlotinib versus docetaxel in second line treatment.
|
26573509 |
2015 |
|
rs61764370
|
|
Squamous cell carcinoma of the head and neck
|
|
0.020 |
GeneticVariation
|
BEFREE |
The TG/GG rs61764370 KRAS-variant is a potential predictive biomarker for poor platinum response in R/M HNSCC patients.
|
25081901 |
2014 |
|
rs61764370
|
|
Breast Carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
KRAS rs61764370 is associated with HER2-overexpressed and poorly-differentiated breast cancer in hormone replacement therapy users: a case control study.
|
22436609 |
2012 |
|
rs61764370
|
|
Endometriosis
|
|
0.020 |
GeneticVariation
|
BEFREE |
Our results do not support the suggestion that carrying the minor allele at rs61764370 contributes to a significant number of endometriosis cases and rs61764370 is, therefore, unlikely to be a useful marker of endometriosis risk.
|
23010532 |
2012 |
|
rs61764370
|
|
Malignant neoplasm of breast
|
|
0.020 |
GeneticVariation
|
BEFREE |
KRAS rs61764370 is associated with HER2-overexpressed and poorly-differentiated breast cancer in hormone replacement therapy users: a case control study.
|
22436609 |
2012 |
|
rs61764370
|
|
Non-Small Cell Lung Carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
Recently, a variant allele in the 3'UTR of the KRAS gene (rs61764370 T>G) was shown to be associated with an increased risk for developing non-small cell lung cancer, as well as ovarian cancer, and was most enriched in ovarian cancer patients from hereditary breast and ovarian cancer families.
|
20676756 |
2011 |
|
rs61764370
|
|
Stage III Gallbladder Cancer AJCC v8
|
|
0.010 |
GeneticVariation
|
BEFREE |
To address this research question, we evaluated whether rs61764370 variant is associated with gallbladder cancer susceptibility and clinical outcomes.
|
27620744 |
2016 |
|
rs61764370
|
|
Gallbladder Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
To address this research question, we evaluated whether rs61764370 variant is associated with gallbladder cancer susceptibility and clinical outcomes.
|
27620744 |
2016 |
|
rs61764370
|
|
Myeloid Leukemia, Chronic
|
|
0.010 |
GeneticVariation
|
BEFREE |
To the best of our knowledge, this study is the first to show a significant association of the KRAS_rs61764370 SNP with CML.
|
27221928 |
2016 |
|
rs61764370
|
|
Stage IIA Gallbladder Cancer AJCC v8
|
|
0.010 |
GeneticVariation
|
BEFREE |
To address this research question, we evaluated whether rs61764370 variant is associated with gallbladder cancer susceptibility and clinical outcomes.
|
27620744 |
2016 |
|
rs61764370
|
|
Stage 0 Gallbladder Cancer AJCC v8
|
|
0.010 |
GeneticVariation
|
BEFREE |
To address this research question, we evaluated whether rs61764370 variant is associated with gallbladder cancer susceptibility and clinical outcomes.
|
27620744 |
2016 |
|
rs61764370
|
|
Stage IIB Gallbladder Cancer AJCC v8
|
|
0.010 |
GeneticVariation
|
BEFREE |
To address this research question, we evaluated whether rs61764370 variant is associated with gallbladder cancer susceptibility and clinical outcomes.
|
27620744 |
2016 |
|
rs61764370
|
|
Sarcoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
The objective of the present study was to explore the molecular mechanism with which a single nucleotide polymorphism (rs61764370) interferes with the interaction between the 3'-untranslated region (3'-UTR) of Kirsten rat sarcoma viral oncogene homolog (KRAS) and let-7a, and its association with the metastasis of osteosarcoma (OS).
|
27430246 |
2016 |
|
rs61764370
|
|
Skin toxicity
|
|
0.010 |
GeneticVariation
|
BEFREE |
This pilot study provides preliminary evidence supporting genetic variation of EGFR (rs2227983), KRAS (rs61764370) and FCGR2A (rs180127) as useful biomarkers for predicting reduced skin toxicity in HNSCC patients treated with a cetuximab-based therapy.
|
27938998 |
2016 |
|
rs61764370
|
|
Stage IV Gallbladder Cancer AJCC v8
|
|
0.010 |
GeneticVariation
|
BEFREE |
To address this research question, we evaluated whether rs61764370 variant is associated with gallbladder cancer susceptibility and clinical outcomes.
|
27620744 |
2016 |
|
rs61764370
|
|
Malignant neoplasm of gallbladder
|
|
0.010 |
GeneticVariation
|
BEFREE |
To address this research question, we evaluated whether rs61764370 variant is associated with gallbladder cancer susceptibility and clinical outcomes.
|
27620744 |
2016 |
|
rs61764370
|
|
Malignant neoplasm of soft tissue
|
|
0.010 |
GeneticVariation
|
BEFREE |
The objective of the present study was to explore the molecular mechanism with which a single nucleotide polymorphism (rs61764370) interferes with the interaction between the 3'-untranslated region (3'-UTR) of Kirsten rat sarcoma viral oncogene homolog (KRAS) and let-7a, and its association with the metastasis of osteosarcoma (OS).
|
27430246 |
2016 |
|
rs61764370
|
|
Dry skin
|
|
0.010 |
GeneticVariation
|
BEFREE |
A significant association with dry skin and global cetuximab-related toxicity was observed for the KRAS-LCS6 (rs61764370) variant (p<0.05); carriers of the G allele (genotypes TG+GG) in the dominant model were observed to have a decreased susceptibility of developing dry skin (OR=0.287 [95%CI=0.119-0.695]).
|
27938998 |
2016 |
|
rs61764370
|
|
Malignant neoplasm of colon and/or rectum
|
|
0.010 |
GeneticVariation
|
BEFREE |
A PubMed search was conducted to identify all studies reporting on KRAS let-7 microRNA-binding site polymorphism (LCS6; rs61764370) and colorectal cancer outcome.
|
24890702 |
2014 |
|
rs61764370
|
|
Secondary malignant neoplasm of colon and/or rectum
|
|
0.010 |
GeneticVariation
|
BEFREE |
Recent studies have reported associations between a variant allele in a let-7 microRNA complementary site (LCS6) within the 3'untranslated region (3'UTR) of KRAS (rs61764370) and clinical outcome in metastatic colorectal cancer (mCRC) patients receiving cetuximab.
|
23167843 |
2012 |
|
rs61764370
|
|
Breast Cancer, Familial
|
|
0.010 |
GeneticVariation
|
BEFREE |
Our data do not support the hypothesis that the KRAS variant rs61764370 is implicated in the aetiology of sporadic or of familial breast cancer.
|
22436609 |
2012 |
|
rs61764370
|
|
Hereditary Breast and Ovarian Cancer Syndrome
|
|
0.010 |
GeneticVariation
|
BEFREE |
Recently, a variant allele in the 3'UTR of the KRAS gene (rs61764370 T>G) was shown to be associated with an increased risk for developing non-small cell lung cancer, as well as ovarian cancer, and was most enriched in ovarian cancer patients from hereditary breast and ovarian cancer families.
|
20676756 |
2011 |
|
rs61764370
|
|
Epithelial ovarian cancer
|
|
0.010 |
GeneticVariation
|
BEFREE |
The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing.
|
21385923 |
2011 |